Therapeutic response of HeberFERON® in patients with basal cell carcinoma and its association with COVID-19

Authors

Keywords:

HeberFERON®, basal cell carcinoma, clinical answer, COVID-19

Abstract

Introduction: basal cell carcinoma is one of the types of skin cancer with the highest incidence. The use of HeberFERON® has shown an effective clinical response.
Objective: to evaluate the response of HeberFERON® in patients with BCC associated with COVID-19 and its behavior in patients with the same dermatological diagnosis without previous treatment with that drug, treated with surgery.
Materials and methods: a descriptive and retrospective observational study was conducted in a universe of 184 adult patients with basal cell carcinoma. The variables analyzed were age, sex, skin phototype, associated comorbidities, SARS-CoV-2 infection, associated to previously treatment with HeberFERON® or surgery; time between treatment received and suffering from COVID-19; severity of symptoms. The results were expressed in tables.
Results: 94 patients were treated with HeberFERON® for basal cell carcinoma, and 90 were treated with surgery. There was a predominance of male patients, aged over 60 years, skin phototype II-III, with cardiovascular morbidities. Of them, 24 (25.5%) were positive to COVID-19 (67.7%), and 83.3% developed mild symptoms. Of those treated with surgery for basal cell carcinoma, 61 were positive to COVID-19 (67,7%), and 55.7% had severe symptoms. During the HeberFERON® treatment cycle for basal cell carcinoma, 66.7% became ill with COVID-19 between 16 and 32 weeks. After 32 weeks one deceased was reported.
Conclusions: patients treated with surgery without prior HeberFERON® had more infections with Covid-19, the deaths associated with it predominating, being less in those who received it. Of those previously treated with HeberFERON® for basal cell carcinoma, 74.5% did not become ill with COVID-19, despite having been 52.8% contacts to SARS-CoV-2 positive people.

Downloads

Download data is not yet available.

Author Biographies

Sandra Cordovés-Quintana, Policlínico Docente 7 de Diciembre. Jagüey Grande, Matanzas

Especialista de primer grado en Dermatología y en Medicina General Integral Profesor instructor

Yusimit Fernández-Brito, Hospital Municipal Docente Iluminado Rodríguez. Jagüey Grande, Matanzas

Especialista de primer grado en Cirugía Maxilofacial

Yisel Piña-Rodríguez, Hospital Universitario Clínico Quirúrgico Comandante Faustino Pérez Hernández. Matanzas

Especialista de primer grado en Dermatología

References

1. Ferrá-Torres TM, Sánchez-Rodríguez ES, Ballester-Caballero Y, et al. Caracterización de pacientes con carcinoma basocelular tratados con HeberFERON. Arch Méd Camag [Internet]. 2020 [citado 01/03/2022];24(2):e7136. Disponible en: https://www.redalyc.org/journal/2111/211166480010/html/

2. López Pupo N, Manganelly Fonseca Y, Tablada Robinet ME, et al. Utilidad del HeberFERON® en pacientes con carcinoma basocelular. Medisan [Internet]. 2021 [citado 01/03/2022];25(6):1297-308. Disponible en: https://www.redalyc.org/journal/3684/368469640002/html/

3. Sánchez Linares V, Cifuentes Suárez JP, Martínez Cuervo JJ, et al. Carcinoma basocelular del rostro tratado con HeberFERON. Gac Méd Espirit [Internet]. 2019 [citado 01/03/2022];21(2):87-97. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1608-89212019000200087&lng=es

4. Sotolongo Díaz D, Vidal Suárez G, Bello Rivero I, et al. La efectividad del HeberFERON® en el tratamiento del Carcinoma Basocelular del dorso de la nariz. Mediciego [Internet]. 2021 [citado 01/03/2022];27(1):1-15. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=104695

5. Castellano Maturell G, Nápoles Pastoriza DD, Niebla Chávez R, et al. HeberFERON® en el tratamiento del carcinoma basocelular. Informe de caso. 16 de Abril [Internet]. 2019 [citado 01/03/2022];58(271):25-8. Disponible en: https://www.semanticscholar.org/paper/HeberFERON%C2%AE-en-el-tratamiento-del-carcinoma-Informe-Maturell-Pastoriza/53e522bb57a958aa6ea539894343f6869a972fce

6. Gómez Martínez N, Gómez Martínez N. Respuesta al tratamiento con Heberferon desde el diagnóstico de enfermería en pacientes con neoplasia basocelular. Rev Cubana Enf [Internet]. 2018 [citado 20/01/2020];34(3):687-95. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=93868

7. Piña Rodríguez Y, Piña Russinyol JJ, Castro Morillo AM, et al. Dermatoscopia para establecer márgenes quirúrgicos mínimos en la resección de carcinomas basocelulares. Rev Méd Electrón [Internet]. 2018 [citado 23/10/2020];40(1):110-19. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1684-18242018000100012&script=sci_arttext

8. Wu PA. Epidemiology, pathogenesis, and clinical features of basal cell carcinoma. UpToDate [Internet]. Irán: MediLib Group; 2018 [citado 23/10/2019]. Disponible en: https://www.uptodate.com/contents/epidemiology-pathogenesis-clinical-features-and-diagnosis-of-basal-cell-carcinoma

9. Rodríguez Fonseca RA, de la Rosa Santana JD, López Wilson A, et al. Tratamiento con HeberFERON® en pacientes con carcinoma basocelular del Hospital Clínico Quirúrgico “Dr. Miguel Enríquez”, La Habana. Gaceta Médica Estudiantil [Internet]. 2020 [citado 20/12/2020];1(2):122-32. Disponible en: http://www.revgacetaestudiantil.sld.cu/index.php/gme/article/view/30/

10. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2017 [Internet]. La Habana: Ministerio de Salud Pública; 2018 [citado 20/12/2020]. Disponible en: https://salud.msp.gob.cu/wp-content/Anuario/anuario_2017_edici%C3%B3n_2018.pdf

11. Ministerio de Salud Pública de Cuba. Protocolo de Actuación Nacional para la Covid-19 [Internet]. La Habana: Ministerio de Salud Pública de Cuba; 2021 [citado 01/03/2022]. Disponible en: https://instituciones.sld.cu/pdvedado/files/2021/02/PROTOCOLO-V.6-FEB.pdf

12. Cabrera Naranjo DL, Sánchez Linares V, Román Simón M, et al. Carcinoma basocelular tratado con HeberFERON, seguimiento clínico, histológico y ecográfico. Reporte de caso. Rev Hum Méd [Internet]. 2020 [citado 01/03/2022];20(3):119-28. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=98496

13. Álvarez Castillo A, Rodríguez Alfaro JM, Salas Boza A. Revisión sistemática del carcinoma basocelular. Rev méd sinerg [Internet]. 2020 [citado 01/03/2022];5(5):e483. Disponible en: http://revistamedicasinergia.com/index.php/rms/article/view/483/

14. Álvarez Salafranca M, Ara M, Zaballos P. Dermatoscopia del carcinoma basocelular: revisión actualizada. Actas Dermosifiliogr [Internet]. 2021 [citado 25/08/2021];112(4):330-8. Disponible en: https://www.sciencedirect.com/science/article/pii/S0001731020305147

15. Ariza S, Espinosa S, Naranjo M. Nonsurgical Therapies for Basal Cell Carcinoma: A Review. Actas Dermosifiliogr [Internet]. 2017 [citado 23/12/2020]:108(9):809-17. Disponible en: https://www.sciencedirect.com/science/article/pii/S1578219017302792

16. Bello Rivero I, García Vega Y, Duncan Roberts Y, et al. HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment. Semin Oncol. 2018;45(1-2):27-33. DOI: 10.1053/j.seminoncol.2018.04.007.

17. Santiesteban Aguilar N, Rosabal Fernández AM. Caracterización clínica e histopatológica del carcinoma baso celular. 2 de Diciembre [Internet]. 2018 [citado 23/10/2019];1(1):37-47. Disponible en: http://revdosdic.sld.cu/index.php/revdosdic/article/view/6/

18. Uribe CJ, Anaya-Reyes KC, Céspedes AM, et al. Carcinoma basocelular de piel en el área metropolitana de Bucaramanga, Colombia: una mirada epidemiológica. Rev Asoc Colomb Dermatol [Internet]. 2018 [citado 23/10/2020];26(1):18-23. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/26

19. Veja Abascal J, Álvarez Fernández A, Ventura Nieves K, et al. Tratamiento con Heberferón® del carcinoma basocelular en la Atención Primaria de Salud en Cuba. Rev Cubana Med Gen Integr [Internet]. 2021 [citado 01/03/2022];37(2):1-13. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=107760

20. Drake-Sosa DV, Rojas-Barlys L. HeberFERON en pacientes con carcinoma basocelular tratados en el municipio Puerto Padre, Las Tunas. Rev electrón “Dr. Zoilo E Marinello Vidaurreta” [Internet]. 2018 [citado 15/01/2019];43(6). Disponible en: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/1573Arts

21. Arts LPJ, Waalboer-Spuij R, Roos KP, et al. Health related quality of life, satisfaction with care, and cosmetic results in relation to treatment among patients with keratinocyte cáncer in the head and neck área: results from the PROFILES Registry. Dermatology [Internet]. 2020 [citado 23/10/2022];236(2):133-42. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212703/

22. Martínez-Díaz E, Pérez-Rodríguez R, Herrera-Martínez L, et al. La industria biofarmacéutica cubana en el combate contra la pandemia de Covid-19. An Acad Cienc Cuba [Internet]. 2020 [citado 23/05/2023];10(2). Disponible en: https://revistaccuba.sld.cu/index.php/revacc/article/view/906

Downloads

Published

2024-01-26

How to Cite

1.
Cordovés-Quintana S, Fernández-Brito Y, Piña-Rodríguez Y, Pérez-Fleitas O. Therapeutic response of HeberFERON® in patients with basal cell carcinoma and its association with COVID-19. Rev Méd Electrón [Internet]. 2024 Jan. 26 [cited 2025 Jan. 23];46:e5159. Available from: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/5159

Issue

Vol. 46 (2024)

Section

Research article

License

All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.

It allows:

 - Copy and redistribute published material in any medium or format.

 - Adapt the content.

 This will be done under the following terms:

 - Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.

 - Non-commercial use.

 - Recognize the journal where it is published.

 The copyrights of each article are maintained, without restrictions.

Most read articles by the same author(s)